KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment
作者： Nicola Normanno , Carmine Pinto , Francesca Castiglione , Alberto Bardelli , Marcello Gambacorta
DOI: 10.1371/JOURNAL.PONE.0029146
关键词: KRAS 、 Genetic testing 、 External quality assessment 、 Mutational analysis 、 Bioinformatics 、 Epidermal growth factor receptor 、 Internal medicine 、 Mutation detection 、 Monoclonal antibody 、 Colorectal cancer 、 Medicine 、 Oncology
摘要: Background Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS mutations. Therefore, testing has become mandatory to chose most appropriate therapy these patients.
harvard.edu
elsevier.com
paperity.org参考文章(19)
Eric R. Fearon, Bert Vogelstein, A genetic model for colorectal tumorigenesis Cell. ,vol. 61, pp. 759- 767 ,(1990) , 10.1016/0092-8674(90)90186-I
Jeanne Tie, Lara Lipton, Jayesh Desai, Peter Gibbs, Robert N Jorissen, Michael Christie, Katharine J Drummond, Benjamin NJ Thomson, Valery Usatoff, Peter M Evans, Adrian W Pick, Simon Knight, Peter WG Carne, Roger Berry, Adrian Polglase, Paul McMurrick, Qi Zhao, Dana Busam, Robert L Strausberg, Enric Domingo, Ian PM Tomlinson, Rachel Midgley, David Kerr, Oliver M Sieber, None, KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer Clinical Cancer Research. ,vol. 17, pp. 1122- 1130 ,(2011) , 10.1158/1078-0432.CCR-10-1720
Nicola Normanno, Sabine Tejpar, Floriana Morgillo, Antonella De Luca, Eric Van Cutsem, Fortunato Ciardiello, Implications for KRAS status and EGFR-targeted therapies in metastatic CRC Nature Reviews Clinical Oncology. ,vol. 6, pp. 519- 527 ,(2009) , 10.1038/NRCLINONC.2009.111
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D'Haens, Tamás Pintér, Robert Lim, György Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 360, pp. 1408- 1417 ,(2009) , 10.1056/NEJMOA0805019
Jean-Yves Douillard, Salvatore Siena, James Cassidy, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, György Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocákova, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean-Luc Canon, Mark Rother, Kelly S Oliner, Michael Wolf, Jennifer Gansert, None, Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study Journal of Clinical Oncology. ,vol. 28, pp. 4697- 4705 ,(2010) , 10.1200/JCO.2009.27.4860
Ellen Bellon, Marjolijn J.L. Ligtenberg, Sabine Tejpar, Karen Cox, Gert Hertogh, Karin Stricker, Anders Edsjö, Vassilis Gorgoulis, Gerald Höfler, Andreas Jung, Athanassios Kotsinas, Pierre Laurent‐Puig, Fernando López‐Ríos, Tine Plato Hansen, Etienne Rouleau, Peter Vandenberghe, Johan J.M. Krieken, Elisabeth Dequeker, External Quality Assessment for KRAS Testing Is Needed: Setup of a European Program and Report of the First Joined Regional Quality Assessment Rounds Oncologist. ,vol. 16, pp. 467- 478 ,(2011) , 10.1634/THEONCOLOGIST.2010-0429
S. E. Baldus, K.-L. Schaefer, R. Engers, D. Hartleb, N. H. Stoecklein, H. E. Gabbert, Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases Clinical Cancer Research. ,vol. 16, pp. 790- 799 ,(2010) , 10.1158/1078-0432.CCR-09-2446
Marc Peeters, Timothy Jay Price, Andrés Cervantes, Alberto F. Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew H. Strickland, Gregory Wilson, Tudor-Eliade Ciuleanu, Laslo Roman, Eric Van Cutsem, Valentina Tzekova, Simon Collins, Kelly S. Oliner, Alan Rong, Jennifer Gansert, Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 28, pp. 4706- 4713 ,(2010) , 10.1200/JCO.2009.27.6055
Rafael G. Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J. Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky, Scott D. Patterson, David D. Chang, Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 26, pp. 1626- 1634 ,(2008) , 10.1200/JCO.2007.14.7116
Daniele Santini, Fotios Loupakis, Bruno Vincenzi, Irene Floriani, Irene Stasi, Emanuele Canestrari, Eliana Rulli, Paolo Enrico Maltese, Francesca Andreoni, Gianluca Masi, Francesco Graziano, Giacomo Giulio Baldi, Lisa Salvatore, Antonio Russo, Giuseppe Perrone, Maria Rosa Tommasino, Mauro Magnani, Alfredo Falcone, Giuseppe Tonini, Annamaria Ruzzo, High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. ,vol. 13, pp. 1270- 1275 ,(2008) , 10.1634/THEONCOLOGIST.2008-0181